Environmental

Low Direct Environmental Footprint: As a clinical-stage biotechnology company, Neuphoria Therapeutics has a limited direct environmental impact compared to manufacturing-based peers, with no evidence of large-scale production or hazardous waste generation at this stage. However, the company does not disclose specific sustainability initiatives or environmental targets, which is increasingly expected in the sector.

Pipeline and R&D Focus: Neuphoria’s operations are primarily R&D-driven, with a high R&D-to-revenue ratio, indicating minimal resource consumption and emissions relative to revenue. This reduces material environmental risks in the near term, but the absence of a formal sustainability framework or reporting leaves potential gaps as the company scales.

Lack of Public Environmental Commitments: There is no evidence of published environmental policies, climate risk assessments, or sustainability disclosures, which places Neuphoria behind leading biotech peers who have adopted ESG reporting and climate action plans.

Neuphoria’s current environmental risk profile is moderate due to its R&D focus and limited operational footprint, but the lack of formal sustainability commitments or disclosures is a notable gap relative to sector best practices.

Social

Clinical Trial Setbacks and Patient Impact: The failure of the AFFIRM-1 Phase 3 trial for social anxiety disorder led to program discontinuation, impacting patients and trial participants. However, the company maintained a strong safety and tolerability profile in its studies, reflecting responsible clinical practices.

Workforce Stability and Capital Allocation: Neuphoria’s high R&D-to-revenue ratio and significant stock-based compensation suggest a focus on talent retention and incentivization, but there is no disclosure of workforce diversity, inclusion, or labor practices, which are material for biotech firms.

Stakeholder Engagement and Transparency: The company has communicated proactively with stockholders regarding strategic reviews and board nominations, but there is limited evidence of broader stakeholder engagement, such as patient advocacy or community involvement, which are increasingly material in the sector.

Neuphoria demonstrates responsible clinical conduct and transparent investor communications, but lacks disclosure on workforce and community practices, limiting its social ESG profile relative to peers.

Governance

Board Expertise and Strategic Review: The board includes nominees with strong investment banking and capital markets backgrounds, which is critical during the ongoing strategic review following clinical setbacks. The board’s focus on continuity and expertise is a positive governance factor.

Shareholder Rights Plan Implementation: The adoption of a limited-duration rights plan (poison pill) in response to a hostile bid demonstrates proactive protection of shareholder interests, though such measures can be controversial if not balanced with openness to value-enhancing proposals.

Active Shareholder Engagement and Proxy Process: Neuphoria has engaged transparently with shareholders regarding board nominations and strategic alternatives, but faces activist pressure and contested board seats, which introduces governance uncertainty and potential for misalignment.

Governance is moderately strong, with a skilled board and transparent processes, but the presence of activist shareholders and the use of a rights plan highlight ongoing risks and the need for careful alignment of interests.

Overall Score

Neuphoria Therapeutics’ ESG profile is moderate across all pillars. The company’s limited operational footprint and responsible clinical practices are offset by a lack of formal ESG disclosures and ongoing governance challenges related to strategic uncertainty and activist involvement. While the board’s expertise and transparent communication are positives, the absence of robust environmental and social frameworks constrains its ESG standing relative to leading biotech peers.